During the third quarter, GDS Wealth Management trimmed its position in UnitedHealth Group by 10.7%, selling 5,297 shares and ending the period with 44,252 shares valued at $15.28 million. Similarly, Cullen Frost Bankers reduced its stake by 27.1%, offloading 29,527 shares and retaining 79,459 shares worth $27.44 million. These two adjustments account for over $42 million in disposals, underscoring a cautious stance among prominent institutional holders. At quarter end, hedge funds and other institutions collectively owned 87.86% of UnitedHealth Group’s outstanding shares, indicating that even modest reallocations by large investors can materially affect trading liquidity and market perception.

In October, five leading brokerages updated their outlooks on UnitedHealth Group. Jefferies raised its target from $317 to $409 and maintained a Buy rating; Goldman Sachs initiated coverage with a Buy and $406 target; UBS lifted its objective from $378 to $430 alongside a Buy recommendation; Piper Sandler trimmed its target slightly to $417 but affirmed an Overweight stance; and Mizuho boosted its price target from $300 to $430 with an Outperform rating. Of the 29 analysts covering the stock, one assigns a Strong Buy, 17 rate it Buy, nine Hold and two Sell, resulting in a consensus “Moderate Buy” rating and average price objective of $386.33. This broad analyst endorsement suggests confidence in UnitedHealth’s ability to sustain revenue growth above 12% year-over-year and deliver EPS growth near 29.5 for the current fiscal year.

UnitedHealth Group generated $113.16 billion in quarterly revenue—up 12.2% year-over-year—and delivered EPS of $2.92, outpacing consensus by $0.05. The company reported a net margin of 4.04% and return on equity of 19.23%. Its debt-to-equity ratio stands at 0.71, with both current and quick ratios at 0.82, reflecting a balanced liquidity position. In December, UnitedHealth paid a quarterly dividend of $2.21, translating to an $8.84 annualized payout and a 46.14% payout ratio. This yield, near decade highs, is underpinned by normalized free cash flow and supports shareholder returns even as the company navigates cost pressures in its Medicare Advantage segment.